• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Hologic Inc.

    11/8/24 4:05:56 PM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email
    8-K
    HOLOGIC INC DE false 0000859737 0000859737 2024-11-05 2024-11-05

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) November 5, 2024

     

     

    HOLOGIC, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    DELAWARE

    (State or Other Jurisdiction of Incorporation)

     

    1-36214   04-2902449
    (Commission File Number)   (I.R.S. Employer Identification No.)

     

    250 Campus Drive, Marlborough, Massachusetts   01752
    (Address of Principal Executive Offices)   (Zip Code)

    (508) 263-2900

    (Registrant’s Telephone Number, Including Area Code)

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act.

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $.01 par value   HOLX   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (e)

    Compensatory Arrangements of Certain Officers

    Approval of revised forms of Performance Stock Unit (“PSU”) Award Agreements. On November 5, 2024, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Hologic, Inc. (the “Company”) approved PSU Award Agreements for fiscal 2025. One form of PSU Award Agreement provides for vesting based on achievement of return on invested capital (“ROIC”) goals, one form of PSU Award Agreement provides for vesting based on three-year relative total shareholder return (“relative TSR”) and one form of PSU Award Agreement provides for vesting based on achievement of free cash flow (“FCF”) goals.

    The above descriptions of the PSU Award Agreements do not purport to be complete and are qualified in their entirety by reference to the applicable PSU Award Agreement, copies of which are attached to this report as Exhibits 10.1, 10.2 and 10.3 and are incorporated herein by reference.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number
       Description
    10.1    Form of Performance Stock Unit Award Agreement (ROIC) (adopted fiscal 2025)
    10.2    Form of Performance Stock Unit Award Agreement (relative TSR) (adopted fiscal 2025)
    10.3    Form of Performance Stock Unit Award Agreement (FCF) (adopted fiscal 2025)
    104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 8, 2024     HOLOGIC, INC.
            By:  

    /s/ John M. Griffin

               

    John M. Griffin

    General Counsel

    Get the next $HOLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    1/12/2026Buy → Hold
    Argus
    1/5/2026$78.00Outperform → In-line
    Evercore ISI
    11/21/2025$79.00Outperform → Neutral
    BNP Paribas Exane
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    More analyst ratings

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic downgraded by Argus

    Argus downgraded Hologic from Buy to Hold

    1/12/26 9:02:06 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Hologic from Outperform to In-line and set a new price target of $78.00

    1/5/26 8:48:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Hologic from Outperform to Neutral and set a new price target of $79.00

    11/21/25 8:06:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

    Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice Hologic, Inc. (NASDAQ:HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic's human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/ Screening for cervical cancer is critically important to women's health. In the United States, it is estimated that in 2026, approximatel

    2/4/26 8:15:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the era of bulky, multi-million dollar hardware is giving way to agile, software-defined diagnostics. As point-of-care tools accelerate toward a $70.92 billion market[2], hospitals are trading dedicated MRI suites for bedside intelligence that delivers hospital-grade precision on a portable device. This seismic shift is placing a massive premium on the

    1/16/26 11:56:00 AM ET
    $BFLY
    $GEHC
    $HOLX
    Medical Electronics
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $HOLX
    SEC Filings

    View All

    SEC Form 8-K filed by Hologic Inc.

    8-K - HOLOGIC INC (0000859737) (Filer)

    2/6/26 8:00:17 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by Hologic Inc.

    10-Q - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:08:35 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by Hologic Inc.

    DEFA14A - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:04:16 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SVP, Human Resources De Walt Diana covered exercise/tax liability with 4,416 shares, decreasing direct ownership by 37% to 7,603 units (SEC Form 4)

    4/A - HOLOGIC INC (0000859737) (Issuer)

    2/3/26 5:11:14 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SVP, Human Resources De Walt Diana covered exercise/tax liability with 4,416 shares, decreasing direct ownership by 37% to 7,603 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    2/3/26 4:19:26 PM ET
    $HOLX
    Medical Electronics
    Health Care

    President, GYN Surgical Schnittker Brandon covered exercise/tax liability with 90 shares, decreasing direct ownership by 0.51% to 17,512 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    12/16/25 4:51:54 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic's pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version on businesswire.com: https://www.businesswire.com/

    1/15/26 7:00:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

    – Revenue of $1,049.5 Million Grows 6.2% – – GAAP Diluted EPS of $0.83 Increases 9.2%, Non-GAAP Diluted EPS of $1.13 Up 11.9% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 27, 2025. The Company reported revenue of $1,049.5 million, GAAP diluted EPS of $0.83, and non-GAAP diluted EPS of $1.13. Highlights On October 21, 2025, the Company announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share (the "Proposed Transaction"). Revenue of $1,049.5 million increased 6.2% for the quarter, or 5.4% in constant currenc

    11/3/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics

    IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    11/11/21 7:26:31 PM ET
    $BEAT
    $GMED
    $GTHX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics